Review



recombinant mouse cd5l rmcd5l  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems recombinant mouse cd5l rmcd5l
    Fig. 1: Lung and liver cancer cell-conditioned media (CM) induce an IL10-like phenotype and <t>CD5L</t> expression in macrophages. a) Principal Component Analysis (PCA) scatterplot of PB monocytes treated for 72 h with medium alone (control), reference activation stimuli
    Recombinant Mouse Cd5l Rmcd5l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse cd5l rmcd5l/product/R&D Systems
    Average 93 stars, based on 6 article reviews
    recombinant mouse cd5l rmcd5l - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Macrophage CD5L is a target for cancer immunotherapy."

    Article Title: Macrophage CD5L is a target for cancer immunotherapy.

    Journal: EBioMedicine

    doi: 10.1016/j.ebiom.2023.104555

    Fig. 1: Lung and liver cancer cell-conditioned media (CM) induce an IL10-like phenotype and CD5L expression in macrophages. a) Principal Component Analysis (PCA) scatterplot of PB monocytes treated for 72 h with medium alone (control), reference activation stimuli
    Figure Legend Snippet: Fig. 1: Lung and liver cancer cell-conditioned media (CM) induce an IL10-like phenotype and CD5L expression in macrophages. a) Principal Component Analysis (PCA) scatterplot of PB monocytes treated for 72 h with medium alone (control), reference activation stimuli

    Techniques Used: Expressing, Control, Activation Assay

    Fig. 2: CD5L expression by TAMs is associated with poor prognosis in papillary lung adenocarcinoma. a) Clinical characteristics of patients diagnosed with Papillary Adenocarcinoma (PAC) who participated in this study. b) Representative immunohistochemistry images showing CD5L expression in early (I) and advanced (II–III) stages of papillary lung adenocarcinoma. Scale bar represents 10 μm. c) Graph shows the number of CD5L+ macrophages per field in early (I, n = 35) and advanced (II–III, n = 20) stages. Data are presented as the mean ± SEM, *p < 0.01 determined by the Mann–Whitney t-test. d) Kaplan–Meier analysis of recurrence-free survival in cases with lower and higher TAM CD5L expression. The mean number of CD5L+ macrophages from stage I was taken as the limit value, *p < 0.01 determined by the Log-rank (Mantel– Cox) test. e) Representative immunofluorescence image depicting CD68+ (red) (i) and CD5L+ (green) macrophages, and their co-expression (orange), (ii). Scale bar represents 25 μm.
    Figure Legend Snippet: Fig. 2: CD5L expression by TAMs is associated with poor prognosis in papillary lung adenocarcinoma. a) Clinical characteristics of patients diagnosed with Papillary Adenocarcinoma (PAC) who participated in this study. b) Representative immunohistochemistry images showing CD5L expression in early (I) and advanced (II–III) stages of papillary lung adenocarcinoma. Scale bar represents 10 μm. c) Graph shows the number of CD5L+ macrophages per field in early (I, n = 35) and advanced (II–III, n = 20) stages. Data are presented as the mean ± SEM, *p < 0.01 determined by the Mann–Whitney t-test. d) Kaplan–Meier analysis of recurrence-free survival in cases with lower and higher TAM CD5L expression. The mean number of CD5L+ macrophages from stage I was taken as the limit value, *p < 0.01 determined by the Log-rank (Mantel– Cox) test. e) Representative immunofluorescence image depicting CD68+ (red) (i) and CD5L+ (green) macrophages, and their co-expression (orange), (ii). Scale bar represents 25 μm.

    Techniques Used: Expressing, Immunohistochemistry, MANN-WHITNEY

    Fig. 3: RImAb specifically binds to human and mouse CD5L and reverts the polarization induced by IL10. a) Direct ELISA of RImAb to hDMBT1, rhCD5, rmCD5L, rhCD5L, or BSA. A representative experiment of three performed is shown. b) RT-qPCR quantification of mRNA expression of CD80, TNFA, CD163, VEGF, MERTK, and CD5L in PB monocytes treated, when indicated, with 5 μg/ml of RImAb for 45 min before the addition of IL10 (50 ng/ml) for 24 h. mRNA levels relative to GAPDH, and fold induction levels were calculated using the expression of each gene in IL10-stimulated macrophages for each donor as a reference. Data are represented as mean ± SEM (n = 5 to 9). Significance was calculated using the Mann–Whitney t-test (*p ≤0.05).
    Figure Legend Snippet: Fig. 3: RImAb specifically binds to human and mouse CD5L and reverts the polarization induced by IL10. a) Direct ELISA of RImAb to hDMBT1, rhCD5, rmCD5L, rhCD5L, or BSA. A representative experiment of three performed is shown. b) RT-qPCR quantification of mRNA expression of CD80, TNFA, CD163, VEGF, MERTK, and CD5L in PB monocytes treated, when indicated, with 5 μg/ml of RImAb for 45 min before the addition of IL10 (50 ng/ml) for 24 h. mRNA levels relative to GAPDH, and fold induction levels were calculated using the expression of each gene in IL10-stimulated macrophages for each donor as a reference. Data are represented as mean ± SEM (n = 5 to 9). Significance was calculated using the Mann–Whitney t-test (*p ≤0.05).

    Techniques Used: Direct ELISA, Quantitative RT-PCR, Expressing, MANN-WHITNEY

    Fig. 4: Blockade of CD5L slows tumor growth in vivo and reprograms TAMs towards an antitumor profile. a) Study design and timeline for mouse model. b) LLC tumor growth in mm3 in mice treated with control (PBS) or the anti-CD5L RImAb. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the two-way repeated measures ANOVA test. c) Left: Immunofluorescence demonstrating CD5L expression (red) by F4/80+ TAMs (green) in control (PBS) and RImAb-treated mice. Nuclei were counterstained with Hoechst 33258 (blue). Scale bars represent 25 μm. Right: graph representing the number of F4/80+ TAMs and F4/80+ TAMs expressing CD5L per field in control and RImAb- treated animals. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the Mann–Whitney t-test. d) Immunohistochemistry depicting expression of F4/80, iNOS, and Arg-1 in tumor samples from control (PBS) and RImAb-treated mice. Scale
    Figure Legend Snippet: Fig. 4: Blockade of CD5L slows tumor growth in vivo and reprograms TAMs towards an antitumor profile. a) Study design and timeline for mouse model. b) LLC tumor growth in mm3 in mice treated with control (PBS) or the anti-CD5L RImAb. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the two-way repeated measures ANOVA test. c) Left: Immunofluorescence demonstrating CD5L expression (red) by F4/80+ TAMs (green) in control (PBS) and RImAb-treated mice. Nuclei were counterstained with Hoechst 33258 (blue). Scale bars represent 25 μm. Right: graph representing the number of F4/80+ TAMs and F4/80+ TAMs expressing CD5L per field in control and RImAb- treated animals. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the Mann–Whitney t-test. d) Immunohistochemistry depicting expression of F4/80, iNOS, and Arg-1 in tumor samples from control (PBS) and RImAb-treated mice. Scale

    Techniques Used: In Vivo, Control, Expressing, MANN-WHITNEY, Immunohistochemistry



    Similar Products

    recombinant mouse cd5l rmcd5l  (R&D Systems)
    93
    R&D Systems recombinant mouse cd5l rmcd5l
    Fig. 1: Lung and liver cancer cell-conditioned media (CM) induce an IL10-like phenotype and <t>CD5L</t> expression in macrophages. a) Principal Component Analysis (PCA) scatterplot of PB monocytes treated for 72 h with medium alone (control), reference activation stimuli
    Recombinant Mouse Cd5l Rmcd5l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse cd5l rmcd5l/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant mouse cd5l rmcd5l - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1: Lung and liver cancer cell-conditioned media (CM) induce an IL10-like phenotype and CD5L expression in macrophages. a) Principal Component Analysis (PCA) scatterplot of PB monocytes treated for 72 h with medium alone (control), reference activation stimuli

    Journal: EBioMedicine

    Article Title: Macrophage CD5L is a target for cancer immunotherapy.

    doi: 10.1016/j.ebiom.2023.104555

    Figure Lengend Snippet: Fig. 1: Lung and liver cancer cell-conditioned media (CM) induce an IL10-like phenotype and CD5L expression in macrophages. a) Principal Component Analysis (PCA) scatterplot of PB monocytes treated for 72 h with medium alone (control), reference activation stimuli

    Article Snippet: Direct binding enzyme-linked immunosorbent assay (ELISA) was performed by immobilizing 5 μg/ml of recombinant human CD5L (rhCD5L),27 recombinant mouse CD5L (rmCD5L) (2834-CL-050, R&D systems, Minneapolis, MN, USA), human DMBT1 (kindly provided by Dr. Martina Tuttolomondo), and human recombinant CD5 (1636-CD-050, R&D systems) in 96-well microtiter plates, overnight at 4 ◦C.

    Techniques: Expressing, Control, Activation Assay

    Fig. 2: CD5L expression by TAMs is associated with poor prognosis in papillary lung adenocarcinoma. a) Clinical characteristics of patients diagnosed with Papillary Adenocarcinoma (PAC) who participated in this study. b) Representative immunohistochemistry images showing CD5L expression in early (I) and advanced (II–III) stages of papillary lung adenocarcinoma. Scale bar represents 10 μm. c) Graph shows the number of CD5L+ macrophages per field in early (I, n = 35) and advanced (II–III, n = 20) stages. Data are presented as the mean ± SEM, *p < 0.01 determined by the Mann–Whitney t-test. d) Kaplan–Meier analysis of recurrence-free survival in cases with lower and higher TAM CD5L expression. The mean number of CD5L+ macrophages from stage I was taken as the limit value, *p < 0.01 determined by the Log-rank (Mantel– Cox) test. e) Representative immunofluorescence image depicting CD68+ (red) (i) and CD5L+ (green) macrophages, and their co-expression (orange), (ii). Scale bar represents 25 μm.

    Journal: EBioMedicine

    Article Title: Macrophage CD5L is a target for cancer immunotherapy.

    doi: 10.1016/j.ebiom.2023.104555

    Figure Lengend Snippet: Fig. 2: CD5L expression by TAMs is associated with poor prognosis in papillary lung adenocarcinoma. a) Clinical characteristics of patients diagnosed with Papillary Adenocarcinoma (PAC) who participated in this study. b) Representative immunohistochemistry images showing CD5L expression in early (I) and advanced (II–III) stages of papillary lung adenocarcinoma. Scale bar represents 10 μm. c) Graph shows the number of CD5L+ macrophages per field in early (I, n = 35) and advanced (II–III, n = 20) stages. Data are presented as the mean ± SEM, *p < 0.01 determined by the Mann–Whitney t-test. d) Kaplan–Meier analysis of recurrence-free survival in cases with lower and higher TAM CD5L expression. The mean number of CD5L+ macrophages from stage I was taken as the limit value, *p < 0.01 determined by the Log-rank (Mantel– Cox) test. e) Representative immunofluorescence image depicting CD68+ (red) (i) and CD5L+ (green) macrophages, and their co-expression (orange), (ii). Scale bar represents 25 μm.

    Article Snippet: Direct binding enzyme-linked immunosorbent assay (ELISA) was performed by immobilizing 5 μg/ml of recombinant human CD5L (rhCD5L),27 recombinant mouse CD5L (rmCD5L) (2834-CL-050, R&D systems, Minneapolis, MN, USA), human DMBT1 (kindly provided by Dr. Martina Tuttolomondo), and human recombinant CD5 (1636-CD-050, R&D systems) in 96-well microtiter plates, overnight at 4 ◦C.

    Techniques: Expressing, Immunohistochemistry, MANN-WHITNEY

    Fig. 3: RImAb specifically binds to human and mouse CD5L and reverts the polarization induced by IL10. a) Direct ELISA of RImAb to hDMBT1, rhCD5, rmCD5L, rhCD5L, or BSA. A representative experiment of three performed is shown. b) RT-qPCR quantification of mRNA expression of CD80, TNFA, CD163, VEGF, MERTK, and CD5L in PB monocytes treated, when indicated, with 5 μg/ml of RImAb for 45 min before the addition of IL10 (50 ng/ml) for 24 h. mRNA levels relative to GAPDH, and fold induction levels were calculated using the expression of each gene in IL10-stimulated macrophages for each donor as a reference. Data are represented as mean ± SEM (n = 5 to 9). Significance was calculated using the Mann–Whitney t-test (*p ≤0.05).

    Journal: EBioMedicine

    Article Title: Macrophage CD5L is a target for cancer immunotherapy.

    doi: 10.1016/j.ebiom.2023.104555

    Figure Lengend Snippet: Fig. 3: RImAb specifically binds to human and mouse CD5L and reverts the polarization induced by IL10. a) Direct ELISA of RImAb to hDMBT1, rhCD5, rmCD5L, rhCD5L, or BSA. A representative experiment of three performed is shown. b) RT-qPCR quantification of mRNA expression of CD80, TNFA, CD163, VEGF, MERTK, and CD5L in PB monocytes treated, when indicated, with 5 μg/ml of RImAb for 45 min before the addition of IL10 (50 ng/ml) for 24 h. mRNA levels relative to GAPDH, and fold induction levels were calculated using the expression of each gene in IL10-stimulated macrophages for each donor as a reference. Data are represented as mean ± SEM (n = 5 to 9). Significance was calculated using the Mann–Whitney t-test (*p ≤0.05).

    Article Snippet: Direct binding enzyme-linked immunosorbent assay (ELISA) was performed by immobilizing 5 μg/ml of recombinant human CD5L (rhCD5L),27 recombinant mouse CD5L (rmCD5L) (2834-CL-050, R&D systems, Minneapolis, MN, USA), human DMBT1 (kindly provided by Dr. Martina Tuttolomondo), and human recombinant CD5 (1636-CD-050, R&D systems) in 96-well microtiter plates, overnight at 4 ◦C.

    Techniques: Direct ELISA, Quantitative RT-PCR, Expressing, MANN-WHITNEY

    Fig. 4: Blockade of CD5L slows tumor growth in vivo and reprograms TAMs towards an antitumor profile. a) Study design and timeline for mouse model. b) LLC tumor growth in mm3 in mice treated with control (PBS) or the anti-CD5L RImAb. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the two-way repeated measures ANOVA test. c) Left: Immunofluorescence demonstrating CD5L expression (red) by F4/80+ TAMs (green) in control (PBS) and RImAb-treated mice. Nuclei were counterstained with Hoechst 33258 (blue). Scale bars represent 25 μm. Right: graph representing the number of F4/80+ TAMs and F4/80+ TAMs expressing CD5L per field in control and RImAb- treated animals. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the Mann–Whitney t-test. d) Immunohistochemistry depicting expression of F4/80, iNOS, and Arg-1 in tumor samples from control (PBS) and RImAb-treated mice. Scale

    Journal: EBioMedicine

    Article Title: Macrophage CD5L is a target for cancer immunotherapy.

    doi: 10.1016/j.ebiom.2023.104555

    Figure Lengend Snippet: Fig. 4: Blockade of CD5L slows tumor growth in vivo and reprograms TAMs towards an antitumor profile. a) Study design and timeline for mouse model. b) LLC tumor growth in mm3 in mice treated with control (PBS) or the anti-CD5L RImAb. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the two-way repeated measures ANOVA test. c) Left: Immunofluorescence demonstrating CD5L expression (red) by F4/80+ TAMs (green) in control (PBS) and RImAb-treated mice. Nuclei were counterstained with Hoechst 33258 (blue). Scale bars represent 25 μm. Right: graph representing the number of F4/80+ TAMs and F4/80+ TAMs expressing CD5L per field in control and RImAb- treated animals. Data are presented as the mean ± SEM (n = 8 per group). *p < 0.01 determined by the Mann–Whitney t-test. d) Immunohistochemistry depicting expression of F4/80, iNOS, and Arg-1 in tumor samples from control (PBS) and RImAb-treated mice. Scale

    Article Snippet: Direct binding enzyme-linked immunosorbent assay (ELISA) was performed by immobilizing 5 μg/ml of recombinant human CD5L (rhCD5L),27 recombinant mouse CD5L (rmCD5L) (2834-CL-050, R&D systems, Minneapolis, MN, USA), human DMBT1 (kindly provided by Dr. Martina Tuttolomondo), and human recombinant CD5 (1636-CD-050, R&D systems) in 96-well microtiter plates, overnight at 4 ◦C.

    Techniques: In Vivo, Control, Expressing, MANN-WHITNEY, Immunohistochemistry